User menu

Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial

Bibliographic reference Jager, J ; Stehouwer, C ; Donker, A ; Bets, D. ; Lehert, Philippe ; et. al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. In: Journal of Internal Medicine, Vol. 257 (2005)
Permanent URL http://hdl.handle.net/2078/18699
  1. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34), 10.1016/s0140-6736(98)07037-8
  2. Ross Russell, Atherosclerosis — An Inflammatory Disease, 10.1056/nejm199901143400207
  3. Stehouwer CDA, Diabetes, 51, 1157 (2002)
  4. Jager A, Diabetes, 49, 485 (2000)
  5. Mather Kieren J, Verma Subodh, Anderson Todd J, Improved endothelial function with metformin in type 2 diabetes mellitus, 10.1016/s0735-1097(01)01129-9
  6. Nagi DK, Diabetes Care, 16, 621 (1993)
  7. Charles MA, Diabetes Care, 21, 1967 (1998)
  8. Grant PJ., Diabetes Care, 19, 64 (1996)
  9. Stehouwer CDA., Eur J Clin Invest, 29, 459 (1999)
  10. Wulffele MG, Diabetes Care, 25, 2133 (2002)
  11. Cockroft DW, Nephron, 16, 31 (1976)
  12. McQueen MJ., Clin Chim Acta, 237, 91 (1995)
  13. Wulffele M. G., Kooy A., Lehert P., Bets D., Ogterop J. C., Burg B., Donker A. J. M., Stehouwer C. D. A., Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial, 10.1046/j.1365-2796.2003.01213.x
  14. Passing H, J Clin Chem Clin Biochem, 21, 709 (1983)
  15. Passing H, J Clin Chem Clin Biochem, 22, 431 (1984)
  16. Scheffer PG, Clin Chem, 43, 1904 (1997)
  17. Scheffer PG, Clin Chem, 44, 2148 (1998)
  18. Stehouwer C, Endothelial dysfunction and pathogenesis of diabetic angiopathy, 10.1016/s0008-6363(96)00272-6
  19. Mannucci P. M., von Willebrand Factor : A Marker of Endothelial Damage?, 10.1161/01.atv.18.9.1359
  20. Vapaatalo H, Med Sci Monit, 7, 1075 (2001)
  21. Blake GJ, Circ Res, 89, 763 (2001)
  22. Ridker Paul M., Hennekens Charles H., Buring Julie E., Rifai Nader, C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women, 10.1056/nejm200003233421202
  23. Grant PJ, Diabet Med, 8, 361 (1991)
  24. Cefalu WT, Diabetes Care, 25, 2123 (2002)
  25. Gregorio F., Ambrosi F., Manfrini S., Velussi M., Carle F., Testa R., Merante D., Filipponi P., Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin, 10.1046/j.1464-5491.1999.00201.x
  26. Albertini J-P, Diabetes Care, 21, 1008 (1998)
  27. Ryysy L, Diabetes Care, 24, 549 (2001)
  28. Abe Y., El-Masri B., Kimball K. T., Pownall H., Reilly C. F., Osmundsen K., Smith C. W., Ballantyne C. M., Soluble Cell Adhesion Molecules in Hypertriglyceridemia and Potential Significance on Monocyte Adhesion, 10.1161/01.atv.18.5.723
  29. St-Pierre AC, Circulation, 104, 2295 (2001)
  30. Vischer UM, Thromb Haemost, 80, 1002 (1998)
  31. Imano E, Diabetes Care, 21, 2135 (1998)
  32. Yki-Järvinen Hannele, Comparison of Bedtime Insulin Regimens in Patients with Type 2 Diabetes Mellitus : A Randomized, Controlled Trial, 10.7326/0003-4819-130-5-199903020-00002
  33. Amador-Licona Norma, Guı́zar-Mendoza Juan-Manuel, Vargas Enrique, Sánchez-Camargo Guillermo, Zamora-Mata Lilia, The Short-Term Effect of a Switch from Glybenclamide to Metformin on Blood Pressure and Microalbuminuria in Patients with Type 2 Diabetes Mellitus, 10.1016/s0188-4409(00)00241-1
  34. Deckert T, Diabetologia, 32, 219 (1989)
  35. Morin-Papunen L, J Clin Endocrinol Metab, 88, 4649 (2003)
  36. Wiernsperger Nicolas F., Metformin: Intrinsic Vasculoprotective Properties, 10.1089/15209150050025230
  37. Kirpichnikov Dmitri, McFarlane Samy I., Sowers James R., Metformin: An Update, 10.7326/0003-4819-137-1-200207020-00009
  38. Libby P., Diabetes Metab, 29, 6S117 (2003)
  39. Beiswenger PJ, Diabetes, 48, 198 (1999)
  40. Ruggiero-Lopez Daniel, Lecomte Marc, Moinet Gérard, Patereau Gérard, Lagarde Michel, Wiernsperger Nicolas, Reaction of metformin with dicarbonyl compounds. possible implication in the inhibition of advanced glycation end product formation, 10.1016/s0006-2952(99)00263-4
  41. Tanaka Yasushi, Uchino Hiroshi, Shimizu Tomoaki, Yoshii Hidenori, Niwa Masataka, Ohmura Chie, Mitsuhashi Naomi, Onuma Tomio, Kawamori Ryuzo, Effect of metformin on advanced glycation endproduct formation and peripheral nerve function in streptozotocin-induced diabetic rats, 10.1016/s0014-2999(99)00342-8
  42. Abasi F, Diabetes Care, 20, 1863 (1997)
  43. Reaven G. M., Combined metformin-sulfonylurea treatment of patients with noninsulin- dependent diabetes in fair to poor glycemic control, 10.1210/jc.74.5.1020
  44. Fujita Hiroki, Fujishima Hiromi, Morii Tsukasa, Koshimura Jun, Narita Takuma, Kakei Masafumi, Ito Seiki, Effect of metformin on adipose tissue resistin expression in db/db mice, 10.1016/s0006-291x(02)02464-6
  45. Fruehwald-Schultes B, Metabolism, 51, 531 (2002)
  46. Kay Joan P., Alemzadeh Ramin, Langley G., D'Angelo L., Smith P., Holshouser S., Beneficial effects of metformin in normoglycemic morbidly obese adolescents, 10.1053/meta.2001.28078
  47. Phillips SA, Diabetes, 52, 667 (2003)
  48. Sivitz WI, J Clin Endocrinol Metab, 88, 1543 (2003)
  49. Bruun JM, Horm Metab Res, 32, 537 (2000)
  50. Solomon SS, Horm Metab Res, 29, 379 (1997)